Jonathan Hunt - IsoRay CFO
CFO
Mr. Jonathan Hunt is CoPrincipal Financial Officer of the Company. Before then, Mr. Hunt was Chief Financial Officer at Vivid Learning Systems, an online safety training company, from 2009 to 2018, where he had a central role in its turnaround, including growing revenues and implementing financial policy and process changes that ultimately resulted in the successful sale of the business. Mr. Hunt previously served as Chief Financial Officer of the Company from 2006 to 2009. Prior to that, Mr. Hunt worked at Hypercom Corporationrationration, a global provider of electronic payment solutions and manufacturer of credit card terminals, where he served as Assistant Corporationrationrate Controller from 2005 to 2006 since 2019.
| Age | 56 |
| Tenure | 6 years |
| Phone | 509 375 1202 |
| Web | https://isoray.com |
Jonathan Hunt Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jonathan Hunt against IsoRay stock is an integral part of due diligence when investing in IsoRay. Jonathan Hunt insider activity provides valuable insight into whether IsoRay is net buyers or sellers over its current business cycle. Note, IsoRay insiders must abide by specific rules, including filing SEC forms every time they buy or sell IsoRay'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jonathan Hunt over six months ago Acquisition by Jonathan Hunt of 100000 shares of Perspective Therapeutics at 10.65 subject to Rule 16b-3 | ||
Jonathan Hunt over six months ago Acquisition by Jonathan Hunt of 1800 shares of Perspective Therapeutics at 9.815 subject to Rule 16b-3 |
IsoRay Management Efficiency
The company has Return on Asset of (0.1085) % which means that on every $100 spent on assets, it lost $0.1085. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.1741) %, meaning that it generated no profit with money invested by stockholders. IsoRay's management efficiency ratios could be used to measure how well IsoRay manages its routine affairs as well as how well it operates its assets and liabilities. Isoray, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. Isoray, Inc. was founded in 1998 and is based in Richland, Washington. Isoray operates under Medical Devices classification in the United States and is traded on AMEX Exchange. It employs 66 people. IsoRay Inc (ISR) is traded on NYSE MKT Exchange in USA and employs 66 people.Management Performance
| Return On Equity | -0.17 | |||
| Return On Asset | -0.11 |
IsoRay Inc Leadership Team
Elected by the shareholders, the IsoRay's board of directors comprises two types of representatives: IsoRay inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IsoRay. The board's role is to monitor IsoRay's management team and ensure that shareholders' interests are well served. IsoRay's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IsoRay's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Austin, Principal Accounting Officer, Co-Principal Financial Officer, Controller | ||
| Alan Hoffmann, Independent Director | ||
| Lisa Lauer, Vice President - Business Development | ||
| Lori Woods, Interim Chief Executive Officer, Director | ||
| Michael McCormick, Independent Chairman of the Board | ||
| Jonathan Hunt, Chief Financial Officer, Co-Principal Financial Officer | ||
| William Cavanagh, Vice President - Research and Development | ||
| Lori HolmesWoods, CEO Director | ||
| Michael Krachon, Vice President, Director of Sales and Marketing | ||
| Jennifer Streeter, Interim Chief Operating Officer, Vice President of Human Resources | ||
| Mark CPA, Controller, Fin | ||
| William III, Chief Officer | ||
| Philip Vitale, Independent Director | ||
| Krista Cline, Senior Director of Operations, Corporate Secretary |
IsoRay Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IsoRay a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.17 | |||
| Return On Asset | -0.11 | |||
| Profit Margin | (1.16) % | |||
| Operating Margin | (1.21) % | |||
| Current Valuation | (11.02 M) | |||
| Shares Outstanding | 278.66 M | |||
| Shares Owned By Insiders | 0.76 % | |||
| Shares Owned By Institutions | 6.18 % | |||
| Number Of Shares Shorted | 409.25 K | |||
| Price To Earning | (5.00) X |
Pair Trading with IsoRay
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if IsoRay position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in IsoRay will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Abbott Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abbott Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abbott Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abbott Laboratories to buy it.
The correlation of Abbott Laboratories is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abbott Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abbott Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abbott Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in IsoRay Stock
If you are still planning to invest in IsoRay Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the IsoRay's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |